LUND, SWEDEN--(Marketwire - Nov 15, 2012) - In accordance with a decision made by the
Annual General Meeting held on May
10, 2012, the Election Committee shall comprise the representatives for the
three largest shareholders, as per end of September 2012, and the Chairman
of
the Board.
For the 2013 Annual General Meeting, the Election Committee shall propose
Board
members and a Chairman of the Board, and fees to Board members and
auditors. The
following individuals were appointed representatives for the largest
shareholders and, accordingly, are members of the Election Committee:
Johnny Sommarlund, MGA Holding
Tomas Billing, Nordstjernan
Martin Bjäringer, representing his own holding and Hajskäret
Invest AB
Under the leadership of the Chairman of the Board, Mats Arnhög, the
Election
Committee shall prepare proposals for the Board of Directors that are to be
presented to and decided upon at the Annual General Meeting on May 15,
2013.
Lund, November 15, 2012
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal
phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, TASQ
for
prostate cancer and ANYARA primarily for the treatment of renal cell
cancer. In
addition, laquinimod is in Phase II development for Crohn's and Lupus. The
company also has one additional project in clinical development, the orally
administered compound 57-57 for Systemic Sclerosis. Please visit
www.activebiotech.com for more information.
Active Biotech's election committee appointed:
http://hugin.info/1002/R/1657773/536293.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Active Biotech via Thomson Reuters ONE
[HUG#1657773]